Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor) Proteins (TFPI)

Human Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor) (TFPI) interaction partners

1. Patients with early onset preeclampsia are characterised by an attenuated coagulation response characterised by reduced thrombin (show F2 Proteins) generation stimulated by low-dose TF and elevated plasma TFPI activity.

2. Developed functional protein S assays that measure both the activated protein C- and TFPI-cofactor activities of protein S in plasma, which are hardly if at all affected by the FV Leiden mutation.

3. These data indicate that both isoforms of TFPI are present in advanced plaques and that anti-inflammatory M2 macrophages may be a potential source of TFPI.

4. Among the various candidate genes involved in acute rejection, CD47 (show CD47 Proteins) inhibits monocyte/macrophage-mediated phagocytosis by identifying the CD47 (show CD47 Proteins) signal regulatory protein alpha (SIRP (show SIRPA Proteins)-alpha) as self/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47 (show CD47 Proteins), thrombospondin-1 (TSP-1 (show THBS1 Proteins)).

5. Tissue Factor Pathway Inhibitor Gene Polymorphism is associated with response to therapy in Colorectal Cancer.

6. For the first time, we show that a TFPI variant is significantly associated with fibrinogen levels and risk of coronary artery disease.

7. miR (show MLXIP Proteins)-27a/b and miR (show MLXIP Proteins)-494 regulate TFPIalpha expression; there may be a role of these miRNAs in the estrogen-mediated downregulation of TFPIalpha

8. Genetic variations of the TFPI genes seem to be related with coronary artery disease, which likely cooperate with metabolic risk factor (diabetes mellitus) and play critical roles in the pathogenesis of coronary artery disease in Han Chinese.

9. Cleavage of FV at Arg(1545) , which abolishes the anticoagulant properties of FV and commits FV to the procoagulant pathway, is inhibited by binding of the TFPIalpha C-terminus to the FV acidic region

10. The aim of this study was to evaluate the concentration of TF and its inhibitor TFPI in blood plasma, the impact of traditional and non-traditional cardiovascular risk factors on their concentration and the impact of both markers of haemostasis on the severity of subclinical atherosclerosis.

Mouse (Murine) Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor) (TFPI) interaction partners

1. endogenous TFPI from vascular smooth muscle cells inhibited ferric chloride-induced arterial thrombosis without causing hemostatic effects

2. TFPI-1 interacts with AMOT (show AMOT Proteins), which led to a decrease in the phosphorylation of YAP (show YAP1 Proteins) and further increased the genes expression of the proliferation and migration involved. Our results further confirmed that atherosclerosis was a localized disease.

3. Results suggest that endothelial cell-anchored TFPI controls lung tumor metastasis, and does so largely through the inhibition of local TF-induced thrombin (show F2 Proteins) generation and the regulation of the lung microenvironment in mice.

4. Data argue against an important role for endogenous TFPI in the antibacterial, inflammatory and procoagulant response during pneumococcal pneumonia.

5. TFPI has an anti-proliferative role in TNF-alpha (show TNF Proteins) stimulated-VSMCs at least partly by interfering with the MCP-3 (show CCL7 Proteins)/CCR2 (show CCR2 Proteins) pathway and then via suppression of the ERK1/2 and PI3K/AKT (show AKT1 Proteins) signaling pathways

6. Results demonstrate that TFPI physiologically modulates thrombin (show F2 Proteins)-dependent platelet activation in a manner that is required for successful embryonic development

7. Tissue factor (show F3 Proteins) plays a hitherto unreported role in the generation of macrophage migratory inhibitory factor by vascular smooth muscle cells in atherosclerosis-prone ApoE (show APOE Proteins)(-/-) mice.

8. The increased plasmin (show PLG Proteins) generation during the early stages of sepsis could cleave/inactivate TFPI and thus lead to thrombotic complications.

9. structural features within residues of the 39-loop contribute to the resistance of FIXa (show ETFB Proteins) to inhibition by plasma inhibitors ZPI (show SERPINA10 Proteins) and TFPI.

10. PAK1 (show PAK1 Proteins) negatively regulates the expression of TFPI and additionally contributes to increased TF activity.

Rabbit Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor) (TFPI) interaction partners

1. Upregulated TF expression and increased plasma TF level during reperfusion period, reduced plasma TFPI-1 level during reperfusion period.

Cow (Bovine) Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor) (TFPI) interaction partners

1. structural features within residues of the 39-loop contribute to the resistance of FIXa (show ETFB Proteins) to inhibition by plasma inhibitors ZPI (show SERPINA10 Proteins) and TFPI.

Zebrafish Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor) (TFPI) interaction partners

1. Knockdown of adtrp1 reduced the expression of tfpi, and hematopoietic defects in adtrp1 morphants were rescued by tfpi overexpression. These data suggest that the regulation of tfpi expression is one potential mechanism by which adtrp1 regulates primitive myelopoiesis and definitive hematopoiesis.